Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 May;27(5):746-747.
doi: 10.1089/thy.2017.0105. Epub 2017 Mar 27.

TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis

Christine C Krieger  1 , Susanne Neumann  1 , Bernice Marcus-Samuels  1 , Marvin C Gershengorn  1
Affiliations
Comment

TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis

Christine C Krieger et al. Thyroid. 2017 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

C.C.K., S.N., and M.C.G. have filed a patent pertaining to drug combinations targeting TSHR and IGF-1R.

Figures

<b>FIG. 1.</b>
FIG. 1.
Competitive binding of thyrotropin (TSH) receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R) antibodies versus Alexa-M22-647. Binding assays on parental HEK-EM cells that do not express TSHRs but endogenous IGF-1Rs and on HEK-TSHR cells were performed by FACS competitive binding of Alexa-647-M22 by incubating cells with 1:25 ratio of Alexa-647-M22 to unlabeled TSHR antibodies M22 and KSAb1, TSH, and IGF-1R antibodies AF305 and 1H7 and IGF-1. Competing ligands were added at 4°C 15 min prior to the addition of Alexa-647-M22 and incubation for 1 h at 4°C. Gray histograms represent auto-fluorescence. Solid-black histograms show Alexa-647-M22 fluorescence intensity. (A) and (B) Alexa-647-M22 non-specifically bound to HEK-EM cells. (C)–(F) The >10-fold peak shift in Alexa-647 fluorescence in HEK-TSHR cells (C) was markedly reduced by unlabeled TSHR antibodies M22 (D) and KSAb1 (E), and partially reduced by TSH (F). (G) and (H) Anti-IGF-1R antibodies AF305 (G), 1H7 (H), and IGF-1 (not shown) did not reduce peak fluorescence.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Smith TJ, Janssen JAMJL. 2017. Building the case for insulin-like receptor-1 involvement in thyroid-associated ophthalmopathy. Front Endocrinol 7:167 - PMC - PubMed
    1. Krieger CC, Place RF, Bevilcqua C, Marcus-Samule B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC. 2016. TSH/IGF-1 receptor cross talk in Graves' ophthalmopathy pathogenesis. J Clin Endocrinol Metab 101:2340–2347 - PMC - PubMed
    1. Kavran JM, McCabe JM, Byrne PO, Connacher MK, Wang Z, Ramek A, Sarabipour S, Shan Y, Shaw DE, Hristova K, Cole PA, Leahy DJ. 2014. How IGF-1 activates its receptor. eLife 3:e03772 - PMC - PubMed
    1. Krieger CC, Gershengorn MC. 2014 A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells. Endocrinology 155:627–634 - PMC - PubMed